LianBio Appoints Jiang Qian as General Manager for China Operations

VCBeat (WeChat: vcbeat) learned on August 3, 2021, that LianBio, a biopharmaceutical company dedicated to bringing disruptive therapies to patients in China and key Asian markets, announced today the appointment of Mr. Qian Jiang as General Manager for China.

“Mr. Qian Jiang has over 25 years of experience in the pharmaceutical industry and has repeatedly led teams to successfully launch drugs, achieving remarkable career accomplishments. We believe that Mr. Qian will play a pivotal role in shaping our China business strategy, establishing our operations in China, and building the infrastructure necessary for product development and commercialization,” said Mr. Konstantin Poukalov, Managing Director at Perceptive Advisors and Executive Chairman of LianBio. “We are proud to welcome Mr. Qian to our team. LianBio will continue to strive forward, committed to bringing more innovative medicines to patients in the future.”

Mr. Qian has extensive experience in successfully launching multiple products in the Chinese market, including Verzenio, Tyvyt, Elunate, Afinitor, Votrient, Sutent, Vfend, and Singulair. In addition, he led the new drug development in China for several global medications, including crizotinib, axitinib, and palbociclib.

Prior to joining LianBio, Mr. Qian served as Vice President of the Oncology Business Unit at Eli Lilly China, where he managed a team of over 700 employees and was responsible for the unit’s profit and loss as well as organizational development. Before joining Eli Lilly, Mr. Qian worked at Novartis Oncology (China) from 2012 to 2018, ultimately serving as Executive Director and Head of the Solid Tumor Division. From 2005 to 2012, he held several key positions at Pfizer, including Head of Business Liaison for the Global Clinical Development and Medical Affairs team at Pfizer’s headquarters, and General Manager of the Oncology Business Unit in China.

Mr. Qian Jiang graduated from the School of Medicine, Shanghai Jiao Tong University (formerly known as Shanghai Second Medical University).

LianBio’s mission is to deliver optimal, science-driven breakthrough therapies to patients in China and other major Asian markets through efficient product development, achieved by forging strategic partnerships with leading global biopharmaceutical companies. By collaborating with world-class partners across diverse therapeutic areas and geographies, LianBio has built a disease-focused product pipeline that leverages translational mechanisms and precision therapies to improve patient outcomes.